麻豆传媒

Case-control study shows reduction in new-onset GA, particularly in nondiabetic patients

Higher rates of progression, interventions, systemic events versus retinopathy without apnea

Significantly lower risk of diabetic macular edema, proliferative diabetic retinopathy

Propensity-matched analysis favored the C3 inhibitor over avacincaptad pegol at 12 and 24 months

Studies show 90% reduction in intravitreal treatment burden, durable effect on vision, anatomy

Positive outcome with UBX-1325 in diabetic macular edema but not wet AMD

AMD treatment burden reduced by 80-90% by implant, intrachoroidal axitinib

Medicare expenditures could jump 15-30%, with similar increases in patients' out-of-pocket costs

Anti-VEGF therapy raises risk of systemic events; retinal effects of diabetes drugs differ

More than a half dozen reports in the last month point to no clear etiology

Also from ASRS: gene therapy for retinitis pigmentosa, anti-VEGF implant matches injection

Longer treatment-free interval with similar vision outcomes versus aflibercept in neovascular AMD

Reoperation rate reduced by three fourths, use expanded to advanced diabetic retinopathy

Subretinal drusenoid deposits found in 85% of patients with AMD and CVD in small study